Clinical stage biotechnology company TORL BioTherapeutics LLC announced on Tuesday the appointment of Howard A. 'Skip' Burris III, MD, FACP, FASCO as a new board member.
Dr Burris is president and chief medical officer for the Sarah Cannon Research Institute (SCRI). He served as the elected president of the American Society of Clinical Oncology (ASCO), holding leadership positions both before and after his ASCO president role, and is an active member of the ASCO community. Dr Burris is also the chair of the board for the ASCO Conquer Cancer Foundation. He was director of clinical research at the Institute for Drug Development of The Cancer Therapy and Research Center and was an associate professor at The University of Texas Health Science Center. He also served in the US Army and attained the rank of lieutenant colonel.
Mark J Alles, chairman and CEO at TORL BioTherapeutics, said: "We are thrilled to have Skip join TORL's board. He is a renowned medical oncologist with decades of success developing first-in-human cancer therapies, many now FDA approved and that have become global standards of care."
NCI reports IND submission for pilot study of Senhwa Biosciences Inc's developed Pidnarulex
Epitomee Medical's Capsule cleared by FDA for weight management
TME Pharma presents promising NOX-A12 trial results at ESMO Congress 2024
Roche's OCREVUS ZUNOVO with Halozyme's ENHANZE drug delivery technology receives FDA approval
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Neuspera Medical names new chief operating officer
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
Dupixent shows promise in treating chronic spontaneous urticaria
Aisa Pharma receives orphan drug designation from FDA for AISA-021(cilnidipine)
Phanes Therapeutics doses first subject in clinical study of PT886 in combination with chemotherapy
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024